Mesenchymal stromal cell therapies: Potential and pitfalls for ARDS

Minerva Anestesiologica

Volumn 81, Issue 2, 2015, Pages 179-194

  C, Masterson ^a,b   M, Jerkic ^b   G f, Curley ^b   Laffey, J G ^a,b  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Acute lung injury; Adult; Inflammation.; Mesenchymal stromal cells; Respiratory distress syndrome

Indexed keywords

LUNG SURFACTANT; REMESTEMCEL L;

ADIPOSE TISSUE; ADULT RESPIRATORY DISTRESS SYNDROME; AMNION FLUID; ANTIMICROBIAL ACTIVITY; ARTICLE; CELL CONTACT; CELL HOMING; CELL POPULATION; CELL TRANSDIFFERENTIATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLEARANCE; CLINICAL TRIAL (TOPIC); ENGRAFTMENT; HUMAN; IMMUNITY; LUNG ALVEOLUS EPITHELIUM; LUNG FLUID; MEMBRANE MICROPARTICLE; MESENCHYMAL STROMA CELL; NONHUMAN; PARACRINE SIGNALING; PATIENT SAFETY; REGENERATION; SEPSIS; STEM CELL TRANSPLANTATION; THERAPY EFFECT; UMBILICAL CORD; UMBILICAL CORD BLOOD; ACUTE LUNG INJURY; MESENCHYMAL STEM CELL TRANSPLANTATION; PROCEDURES; RESPIRATORY DISTRESS SYNDROME, ADULT;

ACUTE LUNG INJURY; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 84930001273     PISSN: 03759393     EISSN: 18271596     Source Type: Journal    
DOI: None     Document Type: Article

References (139)

1. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. Lancet 1967;2:319-23.
2. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012;307:2526-2533.
3. Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M et al. Incidence and outcomes of acute lung injury. N Engl J Med 2005;353:1685-1693.
4. Luhr OR, Antonsen K, Karlsson M, Aardal S, Thorsteinsson A, Frostell CG et al. Incidence and mortality after acute respiratory failure and acute respiratory distress syndrome in Sweden, Denmark, and Iceland. The ARF Study Group. Am J Respir Crit Care Med 1999;159:1849-61.
5. Villar J, Blanco J, Anon JM, Santos-Bouza A, Blanch L, Ambros A et al. The ALIEN study: incidence and outcome of acute respiratory distress syndrome in the era of lung protective ventilation. Intensive Care Med 2011;37:1932-41.
6. Bersten AD, Edibam C, Hunt T, Moran J. Incidence and mortality of acute lung injury and the acute respiratory distress syndrome in three Australian States. Am J Respir Crit Care Med 2002;165:443-8.
7. Ferguson ND, Fan E, Camporota L, Antonelli M, Anzueto A, Beale R et al. The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material. Intensive Care Med 2012;38:1573-82.
8. Erickson SE, Martin GS, Davis JL, Matthay MA, Eisner MD. Recent trends in acute lung injury mortality:1996-2005. Crit Care Med 2009;37:1574-9.
9. Checkley W, Brower R, Korpak A, Thompson BT. Effects of a clinical trial on mechanical ventilation practices in patients with acute lung injury. Am J Respir Crit Care Med 2008;177:1215-22.
10. Li G, Malinchoc M, Cartin-Ceba R, Venkata CV, Kor DJ, Peters SG et al. Eight-year trend of acute respiratory distress syndrome: a population-based study in Olmsted County, Minnesota. Am J Respir Crit Care Med 2011;183:59-66.
11. Hess DR, Thompson BT, Slutsky AS. Update in acute respiratory distress syndrome and mechanical ventilation 2012. Am J Respir Crit Care Med 2013;188:285-92.
12. Friedenstein AJ, Gorskaja JF, Kulagina NN. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Experimental Hematology 1976;4:267-74.
13. Friedenstein AJ, Chailakhjan RK, Lalykina KS. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell and Tissue Kinetics 1970;3:393-403.
14. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006;8:315-7.
15. Greenblatt DJ, Von Moltke LL, Harmatz JS, Shader RI. Pharmacokinetics, pharmacodynamics, and drug disposition. In: Davis KL, Charney D, Coyle JT, Nemeroff C, editor. Neuropsychopharmacology - 5th Generation of Progress. Philadelphia, PA: Lippincott, Williams, & Wilkins; 2002.
16. Chen HT, Lee MJ, Chen CH, Chuang SC, Chang LF, Ho ML et al. Proliferation and differentiation potential of human adipose-derived mesenchymal stem cells isolated from elderly patients with osteoporotic fractures. J Cell Mol Med 2012;16:582-93.
17. Schweitzer KS, Johnstone BH, Garrison J, Rush NI, Cooper S, Traktuev DO et al. Adipose stem cell treatment in mice attenuates lung and systemic injury induced by cigarette smoking. Am J Respir Crit Care Med 2011;183:215-25.
18. Ali HaA-M F. Defining umbilical cord blood stem cells. Stem Cell Discovery 2012;2:15-23.
19. Bieback K, Kern S, Kluter H, Eichler H. Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells 2004;22:625-34.
20. Liu G, Ye X, Zhu Y, Li Y, Sun J, Cui L et al. Osteogenic differentiation of GFP-labeled human umbilical cord blood derived mesenchymal stem cells after cryopreservation. Cryobiology 2011;63:125-8.
21. Zhang X, Hirai M, Cantero S, Ciubotariu R, Dobrila L, Hirsh A et al. Isolation and characterization of mesenchymal stem cells from human umbilical cord blood: reevaluation of critical factors for successful isolation and high ability to proliferate and differentiate to chondrocytes as compared to mesenchymal stem cells from bone marrow and adipose tissue. J Cell Biochem 2011;112:1206-18.
22. Kang XQ, Zang WJ, Bao LJ, Li DL, Song TS, Xu XL et al. Fibroblast growth factor-4 and hepatocyte growth factor induce differentiation of human umbilical cord blood-derived mesenchymal stem cells into hepatocytes. World Journal of Gastroenterology: WJG 2005;11:7461-5.
23. Tio M, Tan KH, Lee W, Wang TT, Udolph G. Roles of dbcAMP, IBMX and RA in aspects of neural differentiation of cord blood derived mesenchymal-like stem cells. PloS One 2010;5:e9398.
24. Klemmt PA, Vafaizadeh V, Groner B. The potential of amniotic fluid stem cells for cellular therapy and tissue engineering. Expert Opin Biol Ther 2011;11:1297-314.
25. Trounson A, Thakar RG, Lomax G, Gibbons D. Clinical trials for stem cell therapies. BMC Medicine 2011;9:52.
26. Tyndall A. Successes and failures of stem cell transplantation in autoimmune diseases. Hematology/the Education Program of the American Society of Hematology American Society of Hematology Education Program 2011;2011:280-284.
27. clinicaltrials.gov. [cited 2015 January 5]. Available from: http://clinicaltrials.gov/
28. Weiss DJ, Casaburi R, Flannery R, LeRoux-Williams M, Tashkin DP. A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest 2013;143:1590-8.
29. Tu Z, Li Q, Bu H, Lin F. Mesenchymal stem cells inhibit complement activation by secreting factor H. Stem Cells Dev 2010;19:1803-9.
30. Salazar KD, Lankford SM, Brody AR. Mesenchymal stem cells produce Wnt isoforms and TGF-beta1 that mediate proliferation and procollagen expression by lung fibroblasts. Am J Physiol Lung Cell Mol Physiol 2009;297:L1002-11.
31. Schena F, Gambini C, Gregorio A, Mosconi M, Reverberi D, Gattorno M et al. Interferon-gamma-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. Arthritis Rheum 2010;62:2776-86.
32. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000;342:1334-9.
33. Bruno S, Grange C, Deregibus MC, Calogero RA, Saviozzi S, Collino F et al. Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J Am Soc Nephrol 2009;20:1053-7.
34. Gatti S, Bruno S, Deregibus MC, Sordi A, Cantaluppi V, Tetta C et al. Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury. Nephrol Dial Transplant 2011;26:1474-83.
35. Kanazawa H, Fujimoto Y, Teratani T, Iwasaki J, Kasahara N, Negishi K et al. Bone marrow-derived mesenchymal stem cells ameliorate hepatic ischemia reperfusion injury in a rat model. PLoS One 2011;6: e19195.
36. Kharaziha P, Hellstrom PM, Noorinayer B, Farzaneh F, Aghajani K, Jafari F et al. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial. Eur J Gastroenterol Hepatol 2009;21:1199-205.
37. Hare JM, Chaparro SV. Cardiac regeneration and stem cell therapy. Curr Opin Organ Transplant 2008;13:536-42.
38. Bustos ML, Huleihel L, Meyer EM, Donnenberg AD, Donnenberg VS, Sciurba JD et al. Activation of human mesenchymal stem cells impacts their therapeutic abilities in lung injury by increasing interleukin (IL)-10 and IL-1RN levels. Stem Cells Transl Med 2013;2:884-95.
39. Chapel A, Bertho JM, Bensidhoum M, Fouillard L, Young RG, Frick J et al. Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome. J Gene Med 2003;5:1028-38.
40. Mei SH, McCarter SD, Deng Y, Parker CH, Liles WC, Stewart DJ. Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. PLoS medicine 2007;4:e269.
41. MacLoughlin RJ, Higgins BD, Laffey JG, O'Brien T. Optimized aerosol delivery to a mechanically ventilated rodent. J Aerosol Med Pulm Drug Deliv 2009;22:323-32.
42. Kotton DN, Fabian AJ, Mulligan RC. Failure of bone marrow to reconstitute lung epithelium. Am J Respir Cell Mol Biol 2005;33:328-34.
43. Frank MH, Sayegh MH. Immunomodulatory functions of mesenchymal stem cells. Lancet 2004;363:1411-2.
44. Nemeth K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009;15:42-9.
45. Lee JW, Gupta N, Serikov V, Matthay MA. Potential application of mesenchymal stem cells in acute lung injury. Expert Opin Biol Ther 2009;9:1259-70.
46. Newman RE, Yoo D, LeRoux MA, Danilkovitch-Miagkova A. Treatment of inflammatory diseases with mesenchymal stem cells. Inflamm Allergy Drug Targets 2009;8:110-23.
47. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005;105:1815-22.
48. Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Aslan H et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 2005;105:2214-9.
49. Ramasamy R, Tong CK, Seow HF, Vidyadaran S, Dazzi F. The immunosuppressive effects of human bone marrow-derived mesenchymal stem cells target T cell proliferation but not its effector function. Cellular Immunology 2008;251:131-6.
50. Wannemuehler TJ, Manukyan MC, Brewster BD, Rouch J, Poynter JA, Wang Y et al. Advances in mesenchymal stem cell research in sepsis. J Surg Res 2012;173:113-26.
51. Sun J, Han ZB, Liao W, Yang SG, Yang Z, Yu J et al. Intrapulmonary delivery of human umbilical cord mesenchymal stem cells attenuates acute lung injury by expanding CD4+CD25+ Forkhead Boxp3 (FOXP3)+ regulatory T cells and balancing anti- and pro-inflammatory factors. Cell Physiol Biochem 2011;27:587-96.
52. Gonzalez-Rey E, Gonzalez MA, Varela N, O'Valle F, Hernandez-Cortes P, Rico L et al. Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Ann Rheum Dis 2010;69:241-8.
53. Prasanna SJ, Gopalakrishnan D, Shankar SR, Vasandan AB. Pro-inflammatory cytokines, IFNgamma and TNFalpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially. PLoS One 2010;5:e9016.
54. Hayes M, Curley G, Ansari B, Laffey JG. Clinical review: Stem cell therapies for acute lung injury/acute respiratory distress syndrome - hope or hype? Crit Care 2012;16:205.
55. Liang ZX, Sun JP, Wang P, Tian Q, Yang Z, Chen LA. Bone marrow-derived mesenchymal stem cells protect rats from endotoxin-induced acute lung injury. Chinese Medical Journal 2011;124:2715-2722.
56. Abraham E. Neutrophils and acute lung injury. Crit Care Med 2003;31:S195-9.
57. Lee JW, Fang X, Gupta N, Serikov V, Matthay MA. Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. Proc Natl Acad Sci U S A 2009;106:16357-62.
58. Xu J, Woods CR, Mora AL, Joodi R, Brigham KL, Iyer S et al. Prevention of endotoxin-induced systemic response by bone marrow-derived mesenchymal stem cells in mice. Am J Physiol Lung Cell Mol Physiol 2007;293:L131-41.
59. Johnston LK, Rims CR, Gill SE, McGuire JK, Manicone AM. Pulmonary macrophage subpopulations in the induction and resolution of acute lung injury. Am J Respir Cell Mol Biol 2012;47:417-26.
60. Guo Z, Zhou X, Li J, Meng Q, Cao H, Kang L et al. Mesenchymal stem cells reprogram host macrophages to attenuate obliterative bronchiolitis in murine orthotopic tracheal transplantation. Int Immunopharmacol 2013;15:726-34.
61. Eisner MD, Thompson T, Hudson LD, Luce JM, Hayden D, Schoenfeld D et al. Efficacy of low tidal volume ventilation in patients with different clinical risk factors for acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med 2001;164:231-6.
62. Doyle RL, Szaflarski N, Modin GW, Wiener-Kronish JP, Matthay MA. Identification of patients with acute lung injury. Predictors of mortality. Am J Respir Crit Care Med 1995;152:1818-24.
63. Krasnodembskaya A, Song Y, Fang X, Gupta N, Serikov V, Lee JW et al. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells 2010;28:2229-38.
64. Mei SH, Haitsma JJ, Dos Santos CC, Deng Y, Lai PF, Slutsky AS et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med 2010;182:1047-57.
65. Gupta N, Su X, Popov B, Lee JW, Serikov V, Matthay MA. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol 2007;179:1855-63.
66. Gupta N, Krasnodembskaya A, Kapetanaki M, Mouded M, Tan X, Serikov V et al. Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia coli pneumonia. Thorax 2012;67:533-9.
67. Flo TH, Smith KD, Sato S, Rodriguez DJ, Holmes MA, Strong RK et al. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 2004;432:917-21.
68. Mutlu GM, Dumasius V, Burhop J, McShane PJ, Meng FJ, Welch L et al. Upregulation of alveolar epithelial active Na+ transport is dependent on beta2-adrenergic receptor signaling. Circ Res 2004;94:1091-00.
69. Guglani L, Gopal R, Rangel-Moreno J, Junecko BF, Lin Y, Berger T et al. Lipocalin 2 regulates inflammation during pulmonary mycobacterial infections. PLoS One 2012;7: e50052.
70. Krasnodembskaya A, Samarani G, Song Y, Zhuo H, Su X, Lee JW et al. Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes. Am J Physiol Lung Cell Mol Physiol 2012;302:L1003-3.
71. Lee JW, Krasnodembskaya A, McKenna DH, Song Y, Abbott J, Matthay MA. Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria. Am J Respir Crit Care Med 2013;187:751-60.
72. Lee JW, Krasnodembskaya A, McKenna DH, Song Y, Abbott J, Matthay MA. Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria. Am J Respir Crit Care Med 2013;187:751-60.
73. Fang X, Neyrinck AP, Matthay MA, Lee JW. Allogeneic human mesenchymal stem cells restore epithelial protein permeability in cultured human alveolar type II cells by secretion of angiopoietin-1. J Biol Chem 2010;285:26211-22.
74. Curley GF, Hayes M, Ansari B, Shaw G, Ryan A, Barry F et al. Mesenchymal stem cells enhance recovery and repair following ventilator-induced lung injury in the rat. Thorax 2012;67:496-501.
75. Curley GF, Ansari B, Hayes M, Devaney J, Masterson C, Ryan A et al. Effects of intratracheal mesenchymal stromal cell therapy during recovery and resolution after ventilator-induced lung injury. Anesthesiology 2013;118:924-32.
76. Liang ZD, Yin XR, Cai DS, Zhou H, Pei L. Autologous transplantation of adipose-derived stromal cells ameliorates ventilator-induced lung injury in rats. J Transl Med 2013;11:179.
77. Curley GF, Contreras M, Higgins B, O'Kane C, McAuley DF, O'Toole D et al. Evolution of the inflammatory and fibroproliferative responses during resolution and repair after ventilator-induced lung injury in the rat. Anesthesiology 2011;115:1022-32.
78. Terragni PP, Rosboch G, Tealdi A, Corno E, Menaldo E, Davini O et al. Tidal hyperinflation during low tidal volume ventilation in acute respiratory distress syndrome. Am J Respir Crit Care Med 2007;175:160-6.
79. Fanelli V, Mascia L, Puntorieri V, Assenzio B, Elia V, Fornaro G et al. Pulmonary atelectasis during low stretch ventilation: "open lung" versus "lung rest" strategy. Crit Care Med 2009;37:1046-53.
80. Maron-Gutierrez T, Silva JD, Asensi KD, Bakker-Abreu I, Shan Y, Diaz BL et al. Effects of mesenchymal stem cell therapy on the time course of pulmonary remodeling depend on the etiology of lung injury in mice. Crit Care Med 2013;41:e319-33.
81. Matthay MA, Ware LB, Zimmerman GA. The acute respiratory distress syndrome. J Clin Invest 2012;122:2731-40.
82. Curley GF, Ansari B, Hayes M, Devaney J, Masterson C, Ryan A et al. Effects of intratracheal mesenchymal stromal cell therapy during recovery and resolution after ventilator-induced lung injury. Anesthesiology 2013;118:924-32.
83. Sartori C, Matthay MA. Alveolar epithelial fluid transport in acute lung injury: new insights. Eur Respir J 2002;20:1299-313.
84. Wang Y, Folkesson HG, Jayr C, Ware LB, Matthay MA. Alveolar epithelial fluid transport can be simultaneously upregulated by both KGF and beta-agonist therapy. J Appl Physiol 1999;87:1852-60.
85. Xu J, Qu J, Cao L, Sai Y, Chen C, He L et al. Mesenchymal stem cell-based angiopoietin-1 gene therapy for acute lung injury induced by lipopolysaccharide in mice. J Pathol 2008;214:472-81.
86. Islam MN, Das SR, Emin MT, Wei M, Sun L, Westphalen K et al. Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nat Med 2012;18:759-65.
87. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008;8:726-36.
88. Augello A, Tasso R, Negrini SM, Amateis A, Indiveri F, Cancedda R et al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 2005;35:1482-90.
89. Zhu YG, Feng XM, Abbott J, Fang XH, Hao Q, Monsel A et al. Human mesenchymal stem cell microvesicles for treatment of E.coli endotoxin-induced acute lung injury in mice. Stem Cells 2014;32:116-25.
90. Welsh DA, Summer WR, Dobard EP, Nelson S, Mason CM. Keratinocyte growth factor prevents ventilator-induced lung injury in an ex vivo rat model. Am J Respir Crit Care Med 2000;162:1081-1086.
91. Cross LJ, O'Kane CM, McDowell C, Elborn JJ, Matthay MA, McAuley DF. Keratinocyte growth factor in acute lung injury to reduce pulmonary dysfunction - a randomised placebo-controlled trial (KARE): study protocol. Trials 2013;14:51.
92. Chen QQ, Yan L, Wang CZ, Wang WH, Shi H, Su BB et al. Mesenchymal stem cells alleviate TNBS-induced colitis by modulating inflammatory and autoimmune responses. World Journal of Gastroenterology:WJG 2013;19:4702-17.
93. Lee JW, Fang X, Krasnodembskaya A, Howard JP, Matthay MA. Concise review: Mesenchymal stem cells for acute lung injury: role of paracrine soluble factors. Stem Cells 2011;29:913-9.
94. Ratajczak J, Miekus K, Kucia M, Zhang J, Reca R, Dvorak P et al. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia 2006;20:847-56.
95. Bruno S, Grange C, Collino F, Deregibus MC, Cantaluppi V, Biancone L et al. Microvesicles derived from mesenchymal stem cells enhance survival in a lethal model of acute kidney injury. PloS one 2012;7:e33115.
96. Deregibus MC, Cantaluppi V, Calogero R, Lo Iacono M, Tetta C, Biancone L et al. Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. Blood 2007;110:2440-8.
97. Kotton DN, Ma BY, Cardoso WV, Sanderson EA, Summer RS, Williams MC et al. Bone marrow-derived cells as progenitors of lung alveolar epithelium. Development 2001;128:5181-8.
98. Krause DS, Theise ND, Collector MI, Henegariu O, Hwang S, Gardner R et al. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell 2001;105:369-77.
99. Chimenti L, Luque T, Bonsignore MR, Ramirez J, Navajas D, Farre R. Pre-treatment with mesenchymal stem cells reduces ventilator-induced lung injury. Eur Respir J 2012;40:939-48.
100. Kang SK, Shin IS, Ko MS, Jo JY, Ra JC. Journey of mesenchymal stem cells for homing: strategies to enhance efficacy and safety of stem cell therapy. Stem Cells International 2012;2012:342968.
101. Kraitchman DL, Tatsumi M, Gilson WD, Ishimori T, Kedziorek D, Walczak P et al. Dynamic imaging of allogeneic mesenchymal stem cells trafficking to myocardial infarction. Circulation 2005;112:1451-61.
102. Gao J, Dennis JE, Muzic RF, Lundberg M, Caplan AI. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells, Tissues, Organs 2001;169:12-20.
103. Fischer UM, Harting MT, Jimenez F, Monzon-Posadas WO, Xue H, Savitz SI et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells and Development 2009;18:683-92.
104. Brooke G, Cook M, Blair C, Han R, Heazlewood C, Jones B et al. Therapeutic applications of mesenchymal stromal cells. Semin Cell Dev Biol 2007;18:846-858.
105. Morando S, Vigo T, Esposito M, Casazza S, Novi G, Principato MC et al. The therapeutic effect of mesenchymal stem cell transplantation in experimental autoimmune encephalomyelitis is mediated by peripheral and central mechanisms. Stem Cell Res Ther 2012;3:3.
106. Matthay MA, Thompson BT, Read EJ, McKenna DH, Jr., Liu KD, Calfee CS et al. Therapeutic potential of mesenchymal stem cells for severe acute lung injury. Chest 2010;138:965-972.
107. Wang J, Liao L, Tan J. Mesenchymal-stem-cell-based experimental and clinical trials: current status and open questions. Expert Opin Biol Ther 2011;11:893-909.
108. Weiss DJ, Casaburi R, Flannery R, Leroux-Williams M, Tashkin DP. A placebo-controlled randomized trial of mesenchymal stem cells in chronic obstructive pulmonary disease. Chest 2013;143:1590-8.
109. Heeschen C, Lehmann R, Honold J, Assmus B, Aicher A, Walter DH et al. Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease. Circulation 2004;109:1615-22.
110. Behr L, Hekmati M, Fromont G, Borenstein N, Noel LH, Lelievre-Pegorier M et al. Intra renal arterial injection of autologous mesenchymal stem cells in an ovine model in the postischemic kidney. Nephron Physiol 2007;107:65-76.
111. de Vasconcelos Dos Santos A, da Costa Reis J, Diaz Paredes B, Moraes L, Jasmin, Giraldi-Guimaraes A et al. Therapeutic window for treatment of cortical ischemia with bone marrow-derived cells in rats. Brain Res 2010;1306:149-58.
112. Liu Y, Zhang, Y. Distribution and differentiation of bone marrow-derived mesenchymal stem cells in vivo after intraperitoneal and tail vein injection into rats in the recovery phase of stroke. Neural Regeneration Research 2010;5.
113. Eggenhofer E, Benseler V, Kroemer A, Popp FC, Geissler EK, Schlitt HJ et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Frontiers in Immunology 2012;3:297.
114. Simmons PJ, Torok-Storb B. Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1. Blood 1991;78:55-62.
115. Battula VL, Treml S, Bareiss PM, Gieseke F, Roelofs H, de Zwart P et al. Isolation of functionally distinct mesenchymal stem cell subsets using antibodies against CD56, CD271, and mesenchymal stem cell antigen-1. Haematologica 2009;94:173-184.
116. Davis JM, Rowley SD, Braine HG, Piantadosi S, Santos GW. Clinical toxicity of cryopreserved bone marrow graft infusion. Blood 1990;75:781-786.
117. Garcia S, Bernad A, Martin MC, Cigudosa JC, Garcia- Castro J, de la Fuente R. Pitfalls in spontaneous in vitro transformation of human mesenchymal stem cells. Exp Cell Res 2010;316:1648-1650.
118. McNulty K, Janes SM. Stem cells and pulmonary fibrosis: cause or cure? Proc Am Thorac Soc 2012;9:164-171.
119. Marshall RP, Bellingan G, Webb S, Puddicombe A, Goldsack N, McAnulty RJ et al. Fibroproliferation occurs early in the acute respiratory distress syndrome and impacts on outcome. Am J Respir Crit Care Med 2000;162:1783-1788.
120. Ankrum J, Karp JM. Mesenchymal stem cell therapy: Two steps forward, one step back. Trends Mol Med 2010;16:203-209.
121. Peister A, Mellad JA, Larson BL, Hall BM, Gibson LF, Prockop DJ. Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential. Blood 2004;103:1662-1668.
122. Tomchuck SL, Zwezdaryk KJ, Coffelt SB, Waterman RS, Danka ES, Scandurro AB. Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses. Stem Cells 2008;26:99-107.
123. Ho AD, Wagner W, Franke W. Heterogeneity of mesenchymal stromal cell preparations. Cytotherapy 2008;10:320-330.
124. Ortiz La, Dutreil M, Fattman C, Pandey AC, Torres G, Go K et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci USA 2007;104:11002-11007.
125. Zhao F, Zhang YF, Liu YG, Zhou JJ, Li ZK, Wu CG et al. Therapeutic effects of bone marrow-derived mesenchymal stem cells engraftment on bleomycin-induced lung injury in rats. Transplantation Proceedings 2008;40:1700-1705.
126. Kumamoto M, Nishiwaki T, Matsuo N, Kimura H, Matsushima K. Minimally cultured bone marrow mesenchymal stem cells ameliorate fibrotic lung injury. Eur Respir J 2009;34:740-748.
127. Danchuk S, Ylostalo JH, Hossain F, Sorge R, Ramsey A, Bonvillain RW et al. Human multipotent stromal cells attenuate lipopolysaccharide-induced acute lung injury in mice via secretion of tumor necrosis factor-alpha-induced protein 6. Stem Cell Res Ther 2011;2:27.
128. Pati S, Gerber MH, Menge TD, Wataha KA, Zhao Y, Baumgartner JA et al. Bone marrow derived mesenchymal stem cells inhibit inflammation and preserve vascular endothelial integrity in the lungs after hemorrhagic shock. PLoS One 2011;6: e25171.
129. Zhang H, Fang J, Su H, Yang M, Lai W, Mai Y et al. Bone marrow mesenchymal stem cells attenuate lung inflammation of hyperoxic newborn rats. Pediatric Transplantation 2012;16:589-598.
130. Song L, Xu J, Qu J, Sai Y, Chen C, Yu L et al. A therapeutic role for mesenchymal stem cells in acute lung injury independent of hypoxia-induced mitogenic factor. J Cell Mol Med 2012;16:376-385.
131. Ionescu L, Byrne RN, van Haaften T, Vadivel A, Alphonse RS, Rey-Parra GJ et al. Stem cell conditioned medium improves acute lung injury in mice: in vivo evidence for stem cell paracrine action. Am J Physiol Lung Cell Mol Physiol 2012;303: L967-977.
132. Darwish I, Banner D, Mubareka S, Kim H, Besla R, Kelvin DJ et al. Mesenchymal stromal (stem) cell therapy fails to improve outcomes in experimental severe influenza. PLoS One 2013;8: e71761.
133. Moodley Y, Atienza D, Manuelpillai U, Samuel CS, Tchongue J, Ilancheran S et al. Human umbilical cord mesenchymal stem cells reduce fibrosis of bleomycin-induced lung injury. Am J Pathol 2009;175:303-313.
134. Chang YS, Choi SJ, Sung DK, Kim SY, Oh W, Yang YS et al. Intratracheal transplantation of human umbilical cord blood-derived mesenchymal stem cells dose-dependently attenuates hyperoxia-induced lung injury in neonatal rats. Cell Transplantation 2011;20:1843-1854.
135. Kim ES, Chang YS, Choi SJ, Kim JK, Yoo HS, Ahn SY et al. Intratracheal transplantation of human umbilical cord blood-derived mesenchymal stem cells attenuates Escherichia coli-induced acute lung injury in mice. Respiratory Research 2011;12:108.
136. Li J, Li D, Liu X, Tang S, Wei F. Human umbilical cord mesenchymal stem cells reduce systemic inflammation and attenuate LPS-induced acute lung injury in rats. J Inflamm (Lond) 2012;9:33.
137. Shin S, Kim Y, Jeong S, Hong S, Kim I, Lee W et al. The therapeutic effect of human adult stem cells derived from adipose tissue in endotoxemic rat model. Int J Med Sci 2013;10:8-18.
138. Zhang S, Danchuk SD, Imhof KM, Semon JA, Scruggs BA, Bonvillain RW et al. Comparison of the therapeutic effects of human and mouse adipose-derived stem cells in a murine model of lipopolysaccharide-induced acute lung injury. Stem Cell Res Ther 2013;4:13.
139. Chang YS, Choi SJ, Ahn SY, Sung DK, Sung SI, Yoo HS et al. Timing of umbilical cord blood derived mesenchymal stem cells transplantation determines therapeutic efficacy in the neonatal hyperoxic lung injury. PLoS One 2013;8: e52419.